First orphan designation ever granted to a condensate-modulating therapeuticBuilds on recent IND opening for DPTX3186, a ...

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

The combination of Merck's Welireg and Eisai's Lenvima has not yet shown statistical significance in extending overall ...

Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer ...

Kids with a rare bone cancer called Ewing sarcoma might live longer if prescribed pazopanib, a drug that blocks blood supply ...

Merck and Eisai's experimental combination treatment for a type of kidney cancer met one of the main goals in a late-stage ...

It's been a roller coaster ride for the drug ever since it was granted accelerated approval in 2020 for the treatment of ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in one combination ...

(Reuters) -The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in one ...

The Food and Drug Administration granted orphan drug designation to Revolution Medicines' treatment for pancreatic cancer. The drug, called daraxonrasib, is being studied in a global phase three ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class ...